Skip to main content

Table 7 Comparative chart of clinical and economic results for treatment of patients with hepatitis C genotype 1

From: Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Therapeutic schedule

Total costs

LY1

QALY2

Result

Peginterferon-alfa-2a + ribavirin

$Brz 31,185

14.51

12.89

peginterferon-alfa-2a is dominant

Peginterferon-alfa-2b + ribavirin

$Brz 39,186

14.35

12.50

 
  1. Notes: 1LYs – Life years; 2QALYs – Quality Adjusted Life Years.